Fig. 10From: Predicting the prognosis, immune response, and immunotherapy in head and neck squamous cell carcinoma using a novel risk model based on anoikis-related lncRNAsEffect of anoikis-related lncRNA signature on chemotherapy response. High-risk HNSCC patients showed significantly low IC50 values for A gemcitabine, B docetaxel, C cisplatin; and D paclitaxelBack to article page